Genentech, Inc. made known on April 8, 2009 the phased voluntary removal of the psoriasis drug Raptiva (efalizumab) from the United States market. Raptiva is used by adults eighteen years or older with chronic moderate-to-severe plaque psoriasis. The company’s decision was determined by the connection of Raptiva with an increased risk of progressive multifocal leukoencephalopathy (PML). This neurological disease is caused by a virus that affects the central nervous system and can be fatal.
Although Raptiva’s prescribing information was updated in October 2008 to include boxed warning on the risk of serious infections, including PML, in patients receiving Raptiva, other serious bacterial and viral infections have been known to occur. Some of the kinds of infections that can be caused by the use of Raptiva are:
- Invasive fungal disease
Unfortunately, as we see in Raptiva, sometimes a prescription or over-the-counter drug intended to help alleviate pain and infection, or reduce pain and suffering, can sometimes cause serious injury or even death. One of the many serious aspects of the Raptiva unsafe drug recall is the fact that a patient risks increased chances of worsening his or her psoriasis condition if Raptiva use is stopped suddenly. This is why it is critical for Raptiva users to consult with their physician as soon as possible to determine an adequate alternative for treatment.
If you or someone you care about has suffered catastrophic injuries from taking the unsafe drug Raptiva or any other prescription drug or over-the-counter medication, the skilled Pennsylvania pharmaceutical litigation lawyers at Anapol Weiss can assist you in evaluating your case.
Having to endure a life threatening adverse Raptiva side effect or experiencing the loss of a loved one who has died as a result of using Raptiva is something no one should have to go through. Find out what your options are for attaining compensation or filing a claim by contacting the Philadelphia personal injury lawyers at Anapol Weiss for your free legal consultation.